• Melanoma
    Categories: ,

    EORTC Melanoma Group changing daily practice for cancer patients

    28 Sep 2020

  • A. Eggermont - ESMO 2020
    Categories: , ,

    PRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Compared Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma

    19 Sep 2020

  • Presentation A. Eggermont at ASCO 2020
    Categories: ,

    EORTC 1325-MG/Keynote 054: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results at three-year median follow-up

    29 May 2020

  • ASCO19 - 18071 study - Prof. Eggermont
    Categories: ,

    Sustained long term survival benefit with adjuvant ipilimumab in patients with high risk stage III melanoma

    1 Jun 2019

  • Melanoma
    Categories: ,

    Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054)

    8 Jan 2018

  • Melanoma
    Categories: ,

    EORTC study published in NEJM shows prolonged survival in stage III melanoma

    8 Oct 2016

  • alexander-eggermont
    Categories: ,

    FDA Approves Adjuvant Yervoy in Melanoma based on results of EORTC trial 18071

    13 Nov 2015

  • alexander-eggermont
    Categories: ,

    Will adjuvant pembrolizumab improve recurrence-free survival for patients with high-risk Stage III melanoma?

    14 Sep 2015